Market closed
Axsome Therapeutics/$AXSM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
$AXSM
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
589
Website
AXSM Metrics
BasicAdvanced
$4.8B
Market cap
-
P/E ratio
-$6.53
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$4.8B
52-week high
$98.40
52-week low
$55.02
Average daily volume
456K
Financial strength
Current ratio
2.442
Quick ratio
2.301
Long term debt to equity
203.872
Total debt to equity
205.623
Interest coverage (TTM)
-48.58%
Management effectiveness
Return on assets (TTM)
-26.44%
Return on equity (TTM)
-171.61%
Valuation
Price to revenue (TTM)
13.997
Price to book
51.87
Price to tangible book (TTM)
148.94
Growth
Revenue change (TTM)
51.47%
Earnings per share change (TTM)
43.89%
3-year earnings per share growth (CAGR)
24.96%
What the Analysts think about AXSM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
AXSM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AXSM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AXSM News
AllArticlesVideos
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 day ago
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
Seeking Alpha·1 day ago
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $4.8B as of November 14, 2024.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of November 14, 2024.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of November 14, 2024.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) does not currently have a Beta indicator.